Iskedjian, Michael; Desjardins, Olivier; Piwko, Charles; … - In: PharmacoEconomics 27 (2009) 2, pp. 149-158
BackgroundBackground Multiple sclerosis (MS) is a chronic neurological disease that affects 240 per 100 000 Canadians. Of these patients, 10-80% (average 70%) experience pain. Sativex is a cannabis-based drug recently approved for neuropathic pain. Abstract: ObjectivesObjectives In this study,...
